What is a beta-2 microglobulin tumor marker test? A beta-2 microglobulin tumor marker test measures the amount of a protein called beta-2 microglobulin (B2M) in your body fluids. The test usually uses a sample of your blood. It may also be done using urine (pee) or in rare cases cerebrospinal fluid (CSF). B2M is a type of tumor marker.

β2 microglobulin (B2M) is a component of MHC class I molecules. MHC class I molecules have α 1, α 2, and α 3 proteins which are present on all nucleated cells (excluding red blood cells). [5][6] In humans, the β 2 microglobulin protein [7] is encoded by the B2M gene. [6][8] β 2 microglobulin lies beside the α 3 chain on the cell surface.

2023年6月8日 · Beta-2 microglobulin (B2M) is a biomarker protein found on the surface of cells, including lymphocytes, and in bodily fluids. B2M is considered a tumor marker because high levels of the antigen may be indicative of certain cancers. In normal biological functioning, B2M is synthesized, excreted and reabsorbed back into the body.

β2-Microglobulin（B2M）是一种小分子球蛋白，作为细胞表面人类淋巴细胞抗原（HLA）的β链（轻链）部分，在生物体内发挥着多重关键作用。 B2M由淋巴细胞、血小板、多形核白细胞产生，其结构和功能在脊椎动物中高度…

2024年1月30日 · 本文将探讨β2微球蛋白的结构、功能以及其在疾病诊断中的应用。 β2微球蛋白是 主要组织相容性复合体 （MHC）类I分子的重要组成部分。 它与 MHC类I分子 的α链非共价结合，帮助稳定MHC类I分子的结构并促进其正确折叠。 这种结合对于将细胞内产生的肽段呈递给免疫系统的 CD8+ T细胞 至关重要，是免疫监视机制中不可或缺的一环。 β2微球蛋白使MHC类I分子能够有效地呈现肽段给CD8+ T细胞，这一过程对于识别和清除体内的病毒感染细胞和肿瘤细胞 …

β2微球蛋白（英語： β 2-microglobulin ，缩写B2M）是MHC1類分子分子的组成部分之一，在所有有核的细胞中（即不包括红细胞）都有表达 [6] [7] 。 在人类基因组中，β2微球蛋白 [ 8 ] 由 B2M 基因 所编码 [ 7 ] [ 9 ] 。

Serum beta-2-microglobulin (B2m) levels were measured in 78 patients with multiple myeloma (MM) and were compared with values for normal individuals and patients with benign monoclonal gammopathies (BMG). Serum B2m levels and values corrected for renal function were significantly higher in patients …

2010年4月20日 · In this report, we document our findings that 1) B2M is an independent predictor of asymptomatic MM progression, and 2) B2M adds prognostic information when combined with the most widely used prognosticators of asymptomatic MM progression.

2010年5月1日 · The current results indicated that 1) serum B2M is an independent predictor of asymptomatic MM progression, and 2) serum B2M adds prognostic information when combined with the most widely used prognosticators of asymptomatic MM progression.

The implications of our results are twofold: i) B2M predicts progression of asymptomatic MM to symptomatic disease independent of conventional risk factors (sMC, BMPC%, light chain burden); ii) B2M refines the conventional model for predicting progression to symptomatic MM by allowing the identification of a very low risk group of patients who ...